文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

抗血管内皮生长因子单药治疗早产儿视网膜病变对眼视网膜及屈光发育的长期影响

LONG-TERM EFFECTS OF ANTI-VEGF MONOTHERAPY FOR RETINOPATHY OF PREMATURITY ON THE RETINAL AND REFRACTIVE DEVELOPMENT OF EYE.
PubMed 文献 · Retina · 2022-01-01

本回顾性病历审查纳入18例(36眼)因1区或后2区早产儿视网膜病变接受贝伐珠单抗、雷珠单抗或阿柏西普单药治疗且矫正年龄≥24个月的儿童,评估视网膜血管成熟、眼轴、屈光及黄斑中心凹发育;三组在荧光素血管造影异常血管发育(P=0.183)或渗漏(P=0.842)上无显著差异,等效球镜均值-0.25±1.82、眼轴20.81±0.62 mm。

要点

  • 三种抗VEGF药物治疗后眼轴与屈光发育相似,周边视网膜异常血管发育亦相似。
  • 荧光素血管造影异常血管发育三组比较P=0.183,渗漏三组比较P=0.842,均无显著差异。
  • 周边视网膜异常血管化的长期影响尚不明确,需确定抗VEGF治疗后随访时长与方法。

核心结论

  • 所有抗VEGF药物均提供相似的充分眼轴与屈光发育,以及相似的周边视网膜异常血管发育。

研究设计与样本

  • 回顾性病历审查研究,纳入有1区或后2区早产儿视网膜病变抗VEGF单药治疗史且矫正年龄至少24个月的儿童,共18例36眼。

主要发现

  • 出生平均孕周27.8±2.13周(范围23-30周),眼部评估在矫正年龄33至61.5个月(均值42.58±8.6个月)进行。
  • 贝伐珠单抗治疗10眼,雷珠单抗治疗14眼,阿柏西普治疗12眼。
  • 等效球镜均值-0.25±1.82,眼轴20.81±0.62 mm。
  • 荧光素血管造影异常视网膜血管发育三组比较P=0.183,渗漏三组比较P=0.842,均无显著差异。

临床怎么用

  • 周边视网膜异常血管化的长期影响尚不明确,作者认为有必要确定早产儿视网膜病变抗VEGF治疗后的随访时长与方法。

局限性

  • 周边视网膜异常血管化的长期影响尚不明确。
  • 作者指出有必要确定抗VEGF治疗后的随访时长与方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate vascular maturation of retina, axial, refractive, and foveal development after anti-VEGF treatment including bevacizumab, ranibizumab, and aflibercept in infants with treatment requiring retinopathy of prematurity (ROP) in long term. METHODS: This retrospective chart review study included children with a history of any anti-VEGF monotherapy for ROP in Zone 1 or posterior Zone 2 who have reached at least 24 months of corrected age. The records of ophthalmologic examination including strabismus evaluation, visual acuity measurement, refractive and axial measurements, optical coherence tomography, and fundus fluorescein angiography examinations with RetCam III were reviewed. RESULTS: A total of 36 eyes of 18 children met the inclusion criteria. The mean gestational age at birth was 27.8 2.13 (23-30) weeks, and ocular assessments were performed between 33 and 61.5 (mean: 42.58 8.6) months of corrected age. Treatment was with bevacizumab in 10 eyes, with ranibizumab in 14 eyes, and with aflibercept in 12 eyes. The mean spherical equivalent was -0.25 1.82; axial length was 20.81 0.62 mm. There was no significant difference among three anti-VEGF groups regarding the abnormal vascular retinal development ( P = 0.183) or leakage ( P = 0.842) on fluorescein angiography. CONCLUSION: All the anti-VEGF agents provided similar adequate axial and refractive development as well as similar abnormal vascular development in the peripheral retina. The long-term impact of this abnormally vascularized peripheral retina is a curiosity issue. From this point of view, it is an important need to determine the follow-up period and method after the anti-VEGF treatment for ROP.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Sukgen EA, Atalay HT, Özdek Ş, et al. LONG-TERM EFFECTS OF ANTI-VEGF MONOTHERAPY FOR RETINOPATHY OF PREMATURITY ON THE RETINAL AND REFRACTIVE DEVELOPMENT OF EYE. Retina. 2022. PMID: 35962999. doi:10.1097/IAE.0000000000003590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。